Risk factors for relapse after reinduction treatment with rituximab in patients with antineutrophil cytoplasmic ...

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for ...

Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory ...

A new case report published in Annals of Internal Medicine describes a novel approach for treating fibrosing mediastinitis ...

“Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory ...

BEIJING, Dec. 09, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today ...

Optimally positioning CD19-directed therapies in the follicular lymphoma treatment sequence requires consideration of both ...

Significant treatment options are changing the management of CLL, according to research presented at the ASH Annual Meeting 2025.

BTK inhibitors work by blocking the BTK enzyme, which plays a role in B cell growth and proliferation. Pirtobrutinib is developed to overcome the tendency for cancer cells to become resistant to ...

Michael Wang, MD, professor at The University of Texas MD Anderson Cancer Center, details the rationale for a long-term ...

During a live event, Matthew Lunning, DO, discussed key factors that determine whether patients should receive CAR T-cell ...

As therapy for chronic lymphocytic leukemia (CLL) continues to evolve, 2025 brought research, regulatory news, and expert ...